Riskpilot← Back to searchSign inGet full accessEndoapex AB
ABActiveOrg 5592769060Hantverkargatan 10Dental practice care activities · NACE 8623Est. 20201 employees
Revenue 2025
SEK 0
EBITDA margin
—
+92% vs 2024
Equity ratio
32.4%
Financial strength
Net profit 2025
SEK -14K
-101% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -71K | +92% |
| Net profit | SEK -14K | -101% |
| Total assets | SEK 781K | -65% |
| Equity | SEK 253K | -79% |
| Employees | 1 | — |
Legal name
Endoapex AB
Org number
5592769060
Legal form
Aktiebolag
NACE code
8623 · Dental practice care activities
Founded
15 oktober 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Tandläkarbehandling i form av specialistvård inom endodonti. Estetiska injektioner.
Address
Hantverkargatan 10
Email
cesar9500@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 81 | 65 | 4 | 0 |
| Staff expenses | — | −247 | −0 | −800 | −0 |
| EBITDA | −704 | 131 | 45 | −929 | −71 |
| Depreciation & amort. | −69 | −49 | — | — | — |
| EBIT | −773 | 81 | 45 | −929 | −71 |
| Net financials | — | −0 | 0 | 3 526 | 7 |
| Profit before tax | −773 | 81 | 45 | 2 117 | −14 |
| Tax | −0 | — | — | −304 | — |
| Net profit | −773 | 81 | 45 | 1 813 | −14 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 502 | 621 | 93 | 2 214 | 781 |
| Equity | −748 | −666 | −621 | 1 191 | 253 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 1 250 | 1 288 | 714 | 543 | 98 |
| Total debt | 1 250 | 1 288 | 714 | 543 | 98 |
EBITDA margin
-7107000.0%
This company
15.8%
Market median
-44981113% vs market
20212025
Equity ratio
32.4%
This company
38.2%
Market median
+15% vs market
20212025
Return on equity
-5.4%
This company
18.4%
Market median
-129% vs market
20212025
Net profit margin
-1369100.0%
This company
8.1%
Market median
-16902569% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
2.09×
This company
0.62×
Market median
-237% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CA Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
RM Authorized Recipient of Service | Authorized Recipient of Service | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Endoapex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Roberto Martin Vidana Törjék | Authorized Recipient of Service | 0 companies |
| Cesar Ariastam | Chief Executive Officer | 0 companies |
| Hadis Khorshidian | Deputy Board Member | 0 companies |